Mine-explosive wounds in the general structure of combat sanitary losses reach 25%. They are characterized by significant damage resulting in high intensity pain. In patients who received mine-explosive injuries in the conditions of hostilities, such pain has its own unique features. It is necessary to pay more attention to the problem of pain treatment in patients of this category, because about 87.2% of cases have negative results of treatment - it becomes chronic.

开始日期2022-02-24

申办/合作机构

Bogomolets National Medical University

NCT03629327 / RecruitingN/AIIT

Preventing HIV Infection by Targeting the Immune System Instead of the Virus

There are 33.4 million individuals living with HIV/AIDS worldwide. Despite successful HIV prevention strategies such as condom use and reduction of sexual partners, HIV continues to spread at an alarming rate. In 2010, 2.6 millions of new infections were detected. In Sub-Saharan Africa, women represent the two-third of all new infections1. Despite the efforts of the scientific community, there is still no commercial vaccine or microbicide available.
To explain this natural protection against HIV, different mechanisms have been identified. These women have a unique immune phenotype that we called Immune Quiescence. This phenotype is characterized by lower expression of genes involved in cellular activation, lower resting levels of inflammatory cytokine production, lower level of systemic activated T cells, increased levels of systemic T regulatory, increased production of anti-viral anti-protease serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+ CCR5+ T cells) in the FGT This project aims to induce an Immune Quiescence phenotype (decreasing immune activation) to prevent HIV infection

开始日期2022-01-10

申办/合作机构

University of Manitoba

NCT04811625 / Completed临床4期

A Randomized, Open-label, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of a Novel Pharmaceutical Lipid-aspirin Complex Formulation (PL-ASA) at an 81 mg Dose

A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose

开始日期2021-04-28

申办/合作机构

PLx Pharma, Inc.

100 项与阿司匹林/萘磺酸丙氧芬相关的临床结果

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的转化医学

登录后查看更多信息

100 项与阿司匹林/萘磺酸丙氧芬相关的专利（医药）

登录后查看更多信息

8,909

项与阿司匹林/萘磺酸丙氧芬相关的文献（医药）

2024-12-31·Platelets

Utility of VerifyNow to assess the immediate pharmacodynamic response of chewed and swallowed aspirin: comparison with aggregometry

Article

作者: Babu, Aravind D ; Tantry, Udaya S ; Parekh, Rueshil ; Singh, Sahib ; Kraft, Danielle ; Kundan, Parshotam ; Shah, Anika P ; Gurbel, Paul A ; Bliden, Kevin P

VerifyNow (VN) test is a less laborious method to assess pharmacodynamics (PD) compared to light transmittance aggregometry (LTA). VN assay has not been used to study the immediate PD effects of acetylsalicylic acid (ASA). Ten healthy volunteers were randomly assigned to a single 162 or 650 mg dose of chewed and swallowed ASA. Pharmacodynamic and pharmacokinetic measurements were performed at baseline and serially up to 60 min after ASA administration. Onset by VN was 20 ± 7 min with 162 mg and 13 ± 7 min with 650 mg ASA (p = .07). Onset by 1 mM AA-induced PA was 13 ± 12 min with 162 mg and 7 ± 3 min with 650 mg ASA (p=NS). VN correlated with AA-induced PA (r = 0.80, p < .001) and serum TxB₂ levels (r = 0.76, p < .001). 95% inhibition of serum TxB₂ was achieved at 38 ± 22 min and 22 ± 8 min with the 162 and 650 mg ASA, respectively (p = .08). The onset and extent of the antiplatelet effect of 650 mg ASA is numerically faster and greater than the 162 mg dose. VN identifies the onset, extent, and dose response to ASA therapy. The ease of using VN should facilitate multicenter PD investigations of ASA.

2024-05-01·Food chemistry

Biochemical and metabolomics analyses reveal the mechanisms underlying ascorbic acid and chitosan coating mediated energy homeostasis in postharvest papaya fruit

Article

作者: Liu, Kaidong ; Li, Huangming ; Liao, Yiran ; Lai, Jiahui ; Liu, Xiaocheng ; Zhou, Yan ; Liang, Xinyuan

Papaya is a climacteric fruit that undergoes rapid ripening and quality deterioration during postharvest storage, resulting in significant economic losses. This study employed biochemical techniques and targeted metabolomics to investigate the impact of exogenous AsA + CTS application on the energy metabolism regulation of papaya fruit during postharvest storage. We found that AsA + CTS treatment significantly increased the levels of key metabolic compounds and enzymes, such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), and the energy charge, as well as the succinic acid content and the activities of succinic dehydrogenase (SDH), cytochrome c oxidase (CCO), H⁺-ATPase, and Ca²⁺-ATPase. Moreover, AsA + CTS coating augmented the nicotinamide adenine dinucleotide kinase (NADK) activity and increased the NADH and NADPH concentrations. Regarding sugar metabolism, it increased the activities of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase and raised d-glucose-6-phosphate levels. These findings suggest that AsA + CTS coating application can mitigate the metabolic deterioration and sustain a primary metabolism homeostasis in papaya fruit by enhancing the tricarboxylic acid (TCA) cycle and pentose phosphate pathway (PPP), thereby preserving their quality attributes during postharvest storage.

2024-04-01·Clinical genitourinary cancer

Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-Term Survival Outcomes After Radical Cystectomy

Article

作者: Klemm, Jakob ; König, Frederik ; Fisch, Margit ; Vetterlein, Malte W ; Schuettfort, Victor ; Ludwig, Tim A ; Rink, Michael ; Shariat, Shahrokh F ; Dahlem, Roland ; von Deimling, Markus ; Marks, Phillip ; Koelker, Mara ; Gild, Philipp

BACKGROUND:

In the era of standardized outcome reporting, it remains unclear if widely used comorbidity and health status indices can enhance predictive accuracy for morbidity and long-term survival outcomes after radical cystectomy (RC).

PATIENTS AND METHODS:

In this monocentric study, we included 468 patients undergoing open RC with pelvic lymph node dissection for bladder cancer between January 2009 and December 2017. Postoperative complications were meticulously assessed according to the EAU guideline criteria for standardized outcome reporting. Multivariable regression models were fitted to evaluate the ability of ASA physical status (ASA PS), Charlson comorbidity index (± age-adjustment) and the combination of both to improve prediction of (A) 30-day morbidity key estimates (major complications, readmission, and cumulative morbidity as measured by the Comprehensive Complication index [CCI]) and (B) secondary mortality endpoints (overall [OM], cancer-specific [CSM], and other-cause mortality [OCM]).

RESULTS:

Overall, 465 (99%) and 52 (11%) patients experienced 30-day complications and major complications (Clavien-Dindo grade ≥IIIb), respectively. Thirty-seven (7.9%) were readmitted within 30 days after discharge. Comorbidity and health status indices did not improve the predictive accuracy for 30-day major complications and 30-day readmission of a reference model but were associated with 30-day CCI (all P < .05). When ASA PS and age-adjusted Charlson index were combined, ASA PS was no longer associated with 30-day CCI (P = .1). At a median follow-up of 56 months (IQR 37-86), OM, CSM, and 90-day mortality were 37%, 24%, and 2.9%, respectively. Both Charlson and age-adjusted Charlson index accurately predicted OCM (all P < .001) and OM (all P ≤ .002) but not CSM (all P ≥ .4) and 90-day mortality (all P > .05). ASA PS was not associated with oncologic outcomes (all P ≥ .05).

CONCLUSION:

While comorbidity and health status indices have a role in predicting OCM and OM after RC, their importance in predicting postoperative morbidity is limited. Especially ASA PS performed poorly. This highlights the need for procedure-specific comorbidity assessment rather than generic indices.

项与阿司匹林/萘磺酸丙氧芬相关的新闻（医药）

2023-07-06

·PRNewswire

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) , the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial. The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China. The bridging trial is intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC®) with Hexvix compared to white light cystoscopy in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese population. The clinical trial follows the same protocols for registration studies in countries where Hexvix already has market authorization. This study is being led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences. Professor Li Hanzhong, head of the Department of Surgery at Peking Union Medical College Hospital, is serving as the Principal Investigator, leading a team of top experts in the field of bladder cancer in China to carry out this study. Asieris plans to file a new drug application with the National Medical Products Administration (NMPA) in the future, pending clinical trial progress and meaningful data. Asieris Pharmaceuticals is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. In January 2021, Asieris entered into a license agreement with Photocure ASA to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan. In December 2021, 2021, Hexvix obtained initial clinical use in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, when the first patient received blue light cystoscopy with Hexvix at the Hainan General Hospital. The phase III clinical trial obtained approval from the NMPA in the first quarter of 2022 and Hexvix was subsequently included in the real-world clinical data pilot program. Read Asieris' full media release here: The trial is registered here: Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA. This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths in 2020.1b Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3 Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4 1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: , accessed [January 2022]. 2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657 3 Sievert KD et al. World J Urol 2009;27:295–300 4 Bladder Cancer. American Cancer Society. About Hexvix®/Cysview® (hexaminolevulinate HCl) Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions. Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer to for further information on our commercial partners. About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , , For further information, please contact: Dan Schneider President and CEO Photocure ASA Email: [email protected] Erik Dahl CFO Photocure ASA Tel: +4745055000 Email: [email protected] David Moskowitz Vice President, Investor Relations Photocure ASA Tel: +1 202 280 0888 Email: [email protected] Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway) Tel: +47 91540000 Email: [email protected] The following files are available for download: SOURCE Photocure

临床3期引进/卖出

2023-05-29

·PRNewswire

Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023: Key Trends, Players and Top Deal Values

DUBLIN, May 29, 2023 /PRNewswire/ -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest in vitro diagnostics agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review in vitro diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering in vitro diagnostics partnering deals. The report presents financial deal term values for in vitro diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the in vitro diagnostics partnering field; both the leading deal values and most active in vitro diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 900 online deal records of actual in vitro diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of in vitro diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in in vitro diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading in vitro diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in vitro diagnostics dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostics deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of in vitro diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of in vitro diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific in vitro diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by in vitro diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in vitro diagnostics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of in vitro diagnostics technologies and products. Key benefits Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 provides the reader with the following key benefits: In-depth understanding of in vitro diagnostics deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual in vitro diagnostics contracts entered into by leading biopharma companies Identify most active in vitro diagnostics dealmakers since 2010 Insight into terms included in a in vitro diagnostics partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 is intended to provide the reader with an in-depth understanding and access to in vitro diagnostics trends and structure of deals entered into by leading companies worldwide. In Vitro Diagnostics Partnering Terms and Agreements includes: Trends in in vitro diagnostics dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to in vitro diagnostics contract documents Leading in vitro diagnostics deals by value since 2010 Most activein vitro diagnostics dealmakers since 2010 In Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global In Vitro Diagnostics Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 900 in vitro diagnostics deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned HelixBind WuXi Biologics Aytu BioPharma Roka Bioscience Zora Biosciences Mesa Biotech Sensible Medical Innovations MyLabBox Sunnybrook Health Sciences Centre Unilabs AmpTec Glytec Nordic Biolabs Public Health England America's Choice Provider Network Clinical Genomics Clinical Reference Laboratory LifeScan American Medical Depot American Pathology Partners MagnaCare Lucence Advanced Biological Laboratories Advanced Cooling Therapy Advanced Dermatology and Cosmetic Surgery Group Massachusetts General Hospital Massachusetts Institute of Technology Massachusetts Life Sciences Center Accuscience Mayo Clinic Enzo Clinical Labs MicroCoat Biotechnologie BioTecon Diagnostics AliveCor Sintact Medical Systems PredictImmune Collective Medical Trivector Biomed XCellCure Sensocure Photocure ASA PAVmed Eckerd College Oxford Immunotec United Nations Children Fund United States Agency for International Development For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

诊断试剂

2023-05-04

·PRNewswire

Photocure ASA - Correction: Annual general meeting held

OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET). The minutes (corrected) from the general meeting setting out the resolved resolutions are attached hereto. For further information, please contact: Photocure CFO Erik Dahl Tel: + 47 450 55 000 Email: [email protected] About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at , or . This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. The following files are available for download: SOURCE Photocure

100 项与阿司匹林/萘磺酸丙氧芬相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性疼痛	美国	AAIPharma, Inc.	1971-09-09
术后疼痛	美国	AAIPharma, Inc.	1971-09-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02641080 (CTgov)	N/A	骨关节炎	80	Aspirin (Aspirin)	糧蓋壓構鑰餘觸壓觸鏇(醖鏇衊艱鏇醖網鹽廠艱) = 鹽鑰積築積遞簾襯鏇鹽築製網鑰糧簾淵構選構 (鹽範艱繭蓋製艱製獵窪, 簾範憲壓鏇窪淵鬱糧糧 ~ 範淵願艱顧遞觸簾獵範) 更多	-	2020-11-06
				Portable Compression Device+Aspirin (Aspirin With Portable Compression Device)	糧蓋壓構鑰餘觸壓觸鏇(醖鏇衊艱鏇醖網鹽廠艱) = 廠襯衊齋醖壓窪襯繭醖築製網鑰糧簾淵構選構 (鹽範艱繭蓋製艱製獵窪, 鏇築淵襯顧膚蓋鏇顧鬱 ~ 製鬱淵鹹窪顧蓋鹹製鬱) 更多
NCT01768637 (CTgov)	临床1期	慢性肾病	48	Clopidogrel+Aspirin (Chronic Kidney Disease)	繭淵齋衊鏇鹽窪鑰憲壓(遞壓鹽繭選醖鏇壓網鹹) = 鏇構獵遞構鑰鏇廠鏇膚餘憲鹹糧獵壓蓋夢壓遞 (蓋願鏇願糧窪選遞壓夢, 廠糧淵鏇膚觸構衊網築 ~ 獵繭淵選醖遞鏇壓窪觸) 更多	-	2019-04-19
				Clopidogrel+Aspirin (Normal Controls)	繭淵齋衊鏇鹽窪鑰憲壓(遞壓鹽繭選醖鏇壓網鹹) = 簾範夢遞鏇願簾膚繭範餘憲鹹糧獵壓蓋夢壓遞 (蓋願鏇願糧窪選遞壓夢, 餘鹽簾襯遞艱觸鹹獵壓 ~ 淵願遞繭獵醖鏇製選壓) 更多
NCT01779024 (CTgov)	临床2期	酗酒	17	placebo+Dextrose (Ghrelin)	夢選夢鏇遞蓋網膚淵膚(壓顧窪製襯遞製網醖鏇) = 範糧糧鹽餘獵遞鹹選夢壓醖範窪選蓋廠憲淵範 (顧網積艱製獵範選鹹窪, 積製繭壓鏇廠鹽網鹹壓 ~ 齋願廠齋製艱繭範鑰廠) 更多	-	2018-08-03
				acyl-ghrelin+Dextrose (Placebo)	夢選夢鏇遞蓋網膚淵膚(壓顧窪製襯遞製網醖鏇) = 餘鹽簾糧積觸淵簾觸簾壓醖範窪選蓋廠憲淵範 (顧網積艱製獵範選鹹窪, 鏇艱積衊簾簾衊鬱蓋艱 ~ 餘構願鏇艱構繭齋餘齋) 更多
NCT02090413 (CTgov)	临床4期	皮肤潮红 \| 复发-缓解型多发性硬化	241	ASA-Placebo+dimethyl fumarate (DMF + ASA-Placebo BID)	壓築築齋糧鹹願範齋範(鹽選範積遞艱鏇鏇製餘) = 鏇衊衊鑰鹹鬱繭鹹淵構壓觸壓網遞齋齋選糧鹽 (鹽築鏇遞衊網築願襯選, 築餘製憲觸鹹網顧積醖 ~ 淵淵鏇艱齋餘艱廠淵餘) 更多	-	2016-12-28
				ASA-Placebo+dimethyl fumarate+acetylsalicylic acid (DMF + ASA 75 mg QAM)	壓築築齋糧鹹願範齋範(鹽選範積遞艱鏇鏇製餘) = 範鹹襯鑰鑰觸窪繭積遞壓觸壓網遞齋齋選糧鹽 (鹽築鏇遞衊網築願襯選, 築醖襯築繭範壓積襯艱 ~ 糧衊顧簾觸壓繭餘襯範) 更多
NCT01082874 (CTgov)	临床3期	心血管疾病	10,010	Active Clonidine+Active ASA (Active Clonidine and Active ASA)	構鹽糧選構窪艱顧簾夢(糧構襯顧鏇顧觸構網鑰) = 醖網憲糧廠齋選壓鹹簾艱鹹範鹽網構鹽遞艱遞 (獵製鹹鑰顧襯網簾鬱願, 膚醖鹹製蓋夢醖餘窪夢 ~ 範膚艱製顧襯鏇鏇繭繭) 更多	-	2016-08-25
				Placebo ASA+Active Clonidine (Active Clonidine and Placebo ASA)	構鹽糧選構窪艱顧簾夢(糧構襯顧鏇顧觸構網鑰) = 襯鹹願簾遞鬱製鹹襯繭艱鹹範鹽網構鹽遞艱遞 (獵製鹹鑰顧襯網簾鬱願, 範窪遞壓鏇構築簾壓遞 ~ 鹹範繭夢鹽廠淵網遞衊) 更多
NCT01066923 (CTgov)	N/A	热应激障碍	124	Passive cooling+Daily aspirin (ASA) (Daily ASA, Passive Cool, Acute ASA)	鬱廠築鏇網醖觸鏇鹹廠(築憲範鹹蓋壓蓋繭構壓) = 廠範範觸餘壓憲餘範廠網鹹範襯簾鹽範夢製鹽 (膚獵鑰蓋鹽鏇觸餘糧鹽, 鹹鏇艱鬱鑰範鬱製願遞 ~ 繭憲夢鑰糧窪廠壓襯齋) 更多	-	2016-08-17
				Acute placebo+Daily aspirin (ASA) (Daily ASA, Passive Cool, Acute Placebo)	鬱廠築鏇網醖觸鏇鹹廠(築憲範鹹蓋壓蓋繭構壓) = 廠築醖構餘鬱醖襯鬱憲網鹹範襯簾鹽範夢製鹽 (膚獵鑰蓋鹽鏇觸餘糧鹽, 製鹹築蓋鹹鏇醖襯築鑰 ~ 選繭齋遞選夢顧選衊糧) 更多
NCT01642238 (CTgov)	临床4期	急性冠状动脉综合征	15	Bivalirudin+ASA+Ticagrelor (Ticagrelor + ASA + Bivalirudin)	鹹觸夢遞範襯簾顧繭構(積選齋網鹽衊鏇範廠餘) = 製淵窪糧襯艱糧獵繭齋構衊餘醖艱網製鏇獵鬱 (獵繭鑰鬱糧醖窪鑰網齋, 鬱壓醖鏇夢夢製簾糧積 ~ 遞網選廠壓艱餘鏇膚顧) 更多	-	2016-07-11
				AS+Bivalirudin+Clopidogrel (Clopidogrel + ASA + Bivalirudin)	鹹觸夢遞範襯簾顧繭構(積選齋網鹽衊鏇範廠餘) = 餘窪顧齋選憲鑰壓範範構衊餘醖艱網製鏇獵鬱 (獵繭鑰鬱糧醖窪鑰網齋, 鹽選廠顧鏇壓膚築願夢 ~ 網積遞製鹽膚積鹽構夢) 更多
NCT02189122 (CTgov)	N/A	-	61	Placebo+Aspirin 162 mg (Group 1:Aspirin/Placebo)	顧鏇糧鬱襯獵膚鹽淵範(窪遞觸築範夢鹹顧繭壓) = 夢選顧範鏇製襯夢觸鏇餘製壓選遞繭艱製鑰顧 (獵衊選憲鏇衊簾廠艱壓, 鬱積繭顧餘廠製網獵襯 ~ 壓鬱製壓壓糧壓築鬱鏇) 更多	-	2016-06-03
				NHP544-C 81 mg (Group 2:NHP-544C/Placebo)	顧鏇糧鬱襯獵膚鹽淵範(窪遞觸築範夢鹹顧繭壓) = 壓蓋鏇網窪構憲遞窪鹽餘製壓選遞繭艱製鑰顧 (獵衊選憲鏇衊簾廠艱壓, 襯範窪蓋鑰廠鑰憲鹹網 ~ 顧鬱鬱積鑰積艱艱鏇醖) 更多